New developments in coronary stent technology

Journal of Interventional Cardiology

Volumn 19, Issue 6, 2006, Pages 493-499

  Smith, Elliot J ^a   Jain, Ajay K ^a   Rothman, Martin T ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PHOSPHORYLCHOLINE; POLYLACTIC ACID; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ATHEROSCLEROTIC PLAQUE; BIOCOMPATIBILITY; BIODEGRADABILITY; BRACHYTHERAPY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; MEDICAL TECHNOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; HUMANS; STENTS;

EID: 33750877094     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2006.00199.x     Document Type: Review

References (51)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
3. British Cardiovascular Intervention Society Audit Return 2004. 05 Sep 2006.
4. Department of Health. The National Service Framework for Coronary Heart Disease. 2000. [Report].
5. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
6. Colombo A. TAXUS-II. 12-month Results. Paris Course on Revascularisation (Euro PCR) 2003, editor. 2003, personal communication.
7. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
8. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-3313.
9. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
10. Morice MC, Serruys PW, Costantini C, et al. Two-Year Follow-Up of the RAVEL Study: A Randomized Study With the Sirolimus-Eluting Bx VELOCITY™ Stent in the Treatment of Patients With De-Novo Native Coronary Artery Lesions. J Am Coll Cardiol 41:32A. 31-3-2003. [Abstract].
11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
12. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
13. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
14. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
15. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004;109:1942-1947.
16. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005;294:1215-1223.
17. Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA 2006;295:1264-1273.
18. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.
19. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
20. Ong AT, van Domburg RT, Aoki J, et al. Sirolimus-eluting stents remain superior to bare-metal stents at two years: Medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006;47:1356-1360.
21. Valgimigli M, Malagutti P, Aoki J, et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: A combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol 2006;47:507-514.
22. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: Comparison with bare metal stent implantation. J Am Coll Cardiol 2005;45:351-356.
23. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and midterm results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-795.
24. Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006;151:1194-1204.
25. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation 2002;106:698-702.
26. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: Predictors of an adverse outcome. J Am Coll Cardiol 2006;47:1949-1958.
27. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-2300.
28. Holmes DR Jr, Leon MB, Moses JW, et al. One-Year Follow-Up of the SIRIUS Study: A Randomized Study With the Sirolimus-Eluting Bx VELOCITY™ in the Treatment of Patients With De-Novo Native Coronary Artery Lesions. J Am Coll Cardiol 41:32A. 19-3-2003. [Abstract].
29. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-953.
30. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
31. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
32. Wang F, Stouffer GA, Waxman S, et al. Late coronary stent thrombosis: Early vs late stent thrombosis in the stent era. Catheter Cardiovasc Interven 2002;55:142-147.
33. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: Success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005;26:1180-1187.
34. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
35. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006;113:2803-2809.
36. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
37. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
38. Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. Eurointervention 2005;157-164.
39. ENDEAVOR II. A randomized trial to evaluate the safety of the Medtronic AVE ABT-578 eluting Driver coronary stent in de novo native coronary lesions. American College of Cardiology Annual Scientific Sessions, 2005.
40. Endeavor. Overview of ABT-578/PC/Cobalt technology and Clinical Trial Program. American College of Cardiology Annual Scientific Sessions, March 2006.
41. Newer Drug Eluting Stent Coatings. American College of Cardiology Annual Scientific Sessions. March 2006.
42. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005;25:748-753.
43. Dibra A, Kastrati A, Mehilli J, et al. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double-blind controlled trial. Catheter Cardiovasc Interven 2005;65:374-380.
44. Mehili J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-279.
45. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
46. Biodegradable Stents. Four-year follow-up. Transcatheter Therapeutics 2004.
47. Tsuji T, Tamai H, Igaki K, et al. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Interven 2003;5:13-16.
48. The Clinical Performance and Angiographic Results of the Coronary Stenting and Absorbable Metal Stents Study. PROGRESS AMS. I2 summit. American College of Cardiology Annual Scientific Sessions, 2006.
49. The Healing II Study. Nine-month Clinical Results. Singapore LIVE Congress, 2006.
50. The Healing II Study. Six-month angiographic results. Transcatheter Therapeutics 2005.
51. Windecker S, Simon R, Lins M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: The TiNOX trial. Circulation 2005;111:2617-2622.